COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

T Kronenberger, SA Laufer, T Pillaiyar - Drug Discovery Today, 2023 - Elsevier
Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …

Methodology-centered review of molecular modeling, simulation, and prediction of SARS-CoV-2

K Gao, R Wang, J Chen, L Cheng, J Frishcosy… - Chemical …, 2022 - ACS Publications
Despite tremendous efforts in the past two years, our understanding of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), virus–host interactions, immune …

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay

A Narayanan, M Narwal, SA Majowicz… - Communications …, 2022 - nature.com
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …

Repurposing molnupiravir for COVID-19: the mechanisms of antiviral activity

AJW Yip, ZY Low, VTK Chow, SK Lal - Viruses, 2022 - mdpi.com
Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

[HTML][HTML] SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?

S Saifi, V Ravi, S Sharma, A Swaminathan… - Genomics, 2022 - Elsevier
The global COVID-19 pandemic continues due to emerging Severe Acute Respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC). Here, we performed …

[HTML][HTML] Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: molecular docking and simulation studies of three pertinent medicinal …

D Verma, D Mitra, M Paul, P Chaudhary… - Current Research in …, 2021 - Elsevier
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-
coronavirus disease 2019 (COVID-19) has raised a severe global public health issue and …

[HTML][HTML] The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review

A Frediansyah - Clinical Epidemiology and Global Health, 2021 - Elsevier
Objective There is no specific antiviral treatment available for coronavirus disease 2019
(COVID-19). Among the possible natural constituents is carrageenan, a polymer derived …

Inhibitory effect of lactoferrin-coated zinc nanoparticles on SARS-CoV-2 replication and entry along with improvement of lung fibrosis induced in adult male albino rats

EM El-Fakharany, H El-Gendi, YA El-Maradny… - International Journal of …, 2023 - Elsevier
Severe acute respiratory syndrome 2019-new coronavirus (SARS-CoV-2) is a major global
challenge caused by a pandemic disease, named 'COVID-19'with no effective and selective …

The Functional Implications of Broad Spectrum Bioactive Compounds Targeting RNA-Dependent RNA Polymerase (RdRp) in the Context of the COVID-19 Pandemic

BA Comunale, RJ Larson, E Jackson-Ward, A Singh… - Viruses, 2023 - mdpi.com
Background: As long as COVID-19 endures, viral surface proteins will keep changing and
new viral strains will emerge, rendering prior vaccines and treatments decreasingly effective …

Possible targets of pan-coronavirus antiviral strategies for emerging or re-emerging coronaviruses

X Li, L Zhang, S Chen, H Ouyang, L Ren - Microorganisms, 2021 - mdpi.com
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which caused
Coronaviruses Disease 2019 (COVID-19) and a worldwide pandemic, is the seventh human …